Alzamend Neuro Files 10-Q, Details Financials
Ticker: ALZN · Form: 10-Q · Filed: Mar 10, 2025 · CIK: 1677077
| Field | Detail |
|---|---|
| Company | Alzamend Neuro, INC. (ALZN) |
| Form Type | 10-Q |
| Filed Date | Mar 10, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, pharmaceutical
TL;DR
Alzamend Neuro 10-Q filed: financials updated for preferred & common stock as of Jan 31, 2025.
AI Summary
Alzamend Neuro, Inc. filed a 10-Q for the period ending January 31, 2025. The company's fiscal year ends on April 30th. The filing details financial information related to preferred stock, common stock, and additional paid-in capital as of October 31, 2023, and October 31, 2024.
Why It Matters
This filing provides investors with an update on Alzamend Neuro's financial position, including details on its capital structure and equity accounts.
Risk Assessment
Risk Level: medium — The filing is a routine 10-Q, but the company operates in the volatile pharmaceutical sector, which inherently carries higher risk.
Key Numbers
- 2025-01-31 — Reporting Period End Date (Indicates the end of the financial reporting period covered by the 10-Q.)
- 2025-03-10 — Filing Date (The date the 10-Q was officially submitted to the SEC.)
- 0430 — Fiscal Year End (Specifies the end date of Alzamend Neuro's fiscal year.)
Key Players & Entities
- Alzamend Neuro, Inc. (company) — Filer of the 10-Q
- 2025-01-31 (date) — End of the reporting period
- 2025-03-10 (date) — Filing date
- 0001677077 (company) — Central Index Key for Alzamend Neuro, Inc.
FAQ
What is the primary business of Alzamend Neuro, Inc.?
Alzamend Neuro, Inc. is primarily involved in the Pharmaceutical Preparations industry, as indicated by its SIC code [2834].
What is the reporting period for this 10-Q filing?
The 10-Q filing is for the period ending January 31, 2025.
When was this 10-Q filed with the SEC?
This 10-Q was filed on March 10, 2025.
What is Alzamend Neuro's fiscal year end?
Alzamend Neuro's fiscal year ends on April 30th.
What specific financial data points are mentioned for October 31, 2023, and October 31, 2024?
The filing mentions Series A Preferred Stock, Series B Preferred Stock, Common Stock, Additional Paid-In Capital, Note Receivable for Common Stock (Related Party), Subscription Receivable for Preferred Stock (Related Party), and Retained Earnings for these dates.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on March 10, 2025 regarding Alzamend Neuro, Inc. (ALZN).